FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer

Journal of Pathology

Volumn 213, Issue 1, 2007, Pages 91-98

  Tomlinson, D C ^a   Baldo, O ^a   Hamden, P ^a   Knowles, M A ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Bladder cancer; FGFR3; Mutation; Over expression; Therapeutic target

Indexed keywords

ARGININE; CYSTEINE; FIBROBLAST GROWTH FACTOR RECEPTOR 3; GLUTAMINE; GLYCINE; LYSINE; SERINE; TYROSINE;

AGED; AMINO ACID SUBSTITUTION; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER STAGING; CARCINOGENESIS; CELL ISOLATION; CELL POPULATION; CODON; CONTROLLED STUDY; DRUG TARGETING; FEMALE; GENE ACTIVATION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LASER CAPTURE MICRODISSECTION; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MORPHOLOGY; MULTIPLE MYELOMA; MUTATION RATE; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR CELL;

AGED; CARCINOMA; DNA MUTATIONAL ANALYSIS; FEMALE; GENE EXPRESSION; GENE FREQUENCY; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICRODISSECTION; MICROSCOPY, CONFOCAL; MUTATION; NEOPLASM STAGING; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; URINARY BLADDER NEOPLASMS;

EID: 34548407864     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2207     Document Type: Article

References (31)

1. Knowles MA. Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis 2006;27:361-373.
2. Wu XR. Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer 2005;5(9):713-725.
3. WHO. Histological typing of urinary bladder tumours. International Histological Classification of Tumours 1973;10.
4. Billerey C, Chopin D, Aubriot-Lorton MH, Ricol D, Gil Diez de Medina S, Van Rhijn B, et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol 2001; 158(6):1955-1959.
5. Cappellen D, De Oliveira C, Ricol D, de Medina S, Bourdin J, Sastre-Garau X, et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 1999; 23(1):18-20.
6. Sibley K, Cuthbert-Heavens D, Knowles MA. Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma. Oncogene 2001;20:686-691.
7. Kimura T, Suzuki H, Ohashi T, Asano K, Kiyota H, Eto Y. The incidence of thanatophoric dysplasia mutations in FGFR3 gene is higher in low-grade or superficial bladder carcinomas. Cancer 2001; 92(10):2555-2561.
8. van Rhijn BW, Lurkin I, Radvanyi F, Kirkels WJ, van der Kwast TH, Zwarthoff EC. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res 2001;61(4):1265-1268.
9. Chesi M, Brents LA, Ely SA, Bais C, Robbiani DF, Mesri EA, et al. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood 2001;97(3):729-736.
10. Matsumoto M, Ohtsuki Y, Ochii K, Seike Y, Iseda N, Sasaki T, et al. Fibroblast growth factor receptor 3 protein expression in urothelial carcinoma of the urinary bladder, exhibiting no association with low-grade and/or non-invasive lesions. Oncol Rep 2004; 12(5):967.
11. Gomez-Roman JJ, Saenz P, Molina M, Cuevas Gonzalez J, Escuredo K, Santa Cruz S, et al. Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth. Clin Cancer Res 2005;11(2 Pt 1):459.
12. Mhawech-Fauceglia P, Cheney RT, Fischer G, Beek A, Herrmann FR. FGFR3 and p53 protein expressions in patients with pTa and pT1 urothelial bladder cancer. Eur J Surg Oncol 2006;32(2):231-237.
13. Bernard-Pierrot I, Brams A, Dunois-Larde C, Caillault A, Diez de Medina SG, Cappellen D, et al. Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b. Carcinogenesis 2006; 27(4):740-747.
14. Chen J, Williams IR, Lee BH, Duclos N, Huntly BJ, Donoghue DJ, et al. Constitutively activated FGFR3 mutants signal through PLCχ-dependent and -independent pathways for hematopoietic transformation. Blood 2005;106(l):328-337.
15. Grand EK, Chase AJ, Heath C, Rahemtulla A, Cross NC. Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074. Leukemia 2004;18(5):962-966.
16. Trudel S, Ely S, Farooqi Y, Affer M, Robbiani DF, Chesi M, et al. Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma. Blood 2004; 103(9):3521-3528.
17. Trudel S, Li ZH, Wei E, Wiesmann M, Chang H, Chen C, et al. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood 2005; 105(7):2941.
18. Trudel S, Stewart AK, Rom E, Wei E, Li ZH, Kotzer S, et al. The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells. Blood 2006;107(10):4039-4046.
19. Tomlinson DC, Hurst CD, Knowles MA. Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer. Oncogene 2007. DOI: 10.1002/si.onc.1210399.
20. UICC. TNM classification of malignant tumors, bladder. In. 3 ed: Union Internationale Contre le Cancer: Geneva; 1978; p. 113-117.
21. Jebar AH, Hurst CD, Tomlinson DC, Johnston C, Taylor CF, Knowles MA. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene 2005;24(33):5218-5225.
22. van Rhijn BW, Vis AN, van der Kwast TH, Kirkels WJ, Radvanyi F, Ooms EC, et al. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MTB-I is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol 2003; 21(10):1912-1921.
23. Hernandez S, Lopez-Knowles E, Lloreta J, Kogevinas M, Amoros A, Tardon A, et al. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol 2006;24(22):3664-3671.
24. Zieger K, Dyrskjot L, Wiuf C, Jensen JL, Andersen CL, Jensen KM, et al. Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors. Clin Cancer Res 2005; 11(21):7709-7719.
25. Rieger-Christ KM, Mourtzinos A, Lee PJ, Zagha RM, Cain J, Silverman M, et al. Identification of fibroblast growth factor receptor 3 mutations in urine sediment DNA samples complements cytology in bladder tumor detection. Cancer 2003;98(4):737-744.
26. van Rhijn BW, Montironi R, Zwarthoff EC, Jobsis AC, van der Kwast TH. Frequent FGFR3 mutations in urothelial papilloma. J Pathol 2002; 198(2):245-251.
27. van Rhijn BW, Lurkin I, Chopin DK, Kirkels WJ, Thiery JP, van der Kwast TH, et al. Combined microsatellite and FGFR3 mutation analysis enables a highly sensitive detection of urothelial cell carcinoma in voided urine. Clin Cancer Res 2003;9(1):257-263.
28. van Oers JM, Lurkin I, van Exsel AJ, Nijsen Y, van Rhijn BW, van der Aa MN, et al. A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine. Clin Cancer Res 2005;11(21):7743-7748.
29. Munro NP, Knowles MA. Fibroblast growth factors and their receptors in transitional cell carcinoma. J Urol 2003;169(2): 675-682.
30. Tomlinson DC, L'Hote CG, Kennedy W, Pitt E, Knowles MA. Alternative splicing of fibroblast growth factor receptor 3 produces a secreted isoform that inhibits fibroblast growth factor-induced proliferation and is repressed in urothelial carcinoma cell lines. Cancer Res 2005;65(22):10441-10449.
31. Martinez-Torrecuadrada J, Cifuentes G, Lopez-Seffa P, Saenz P, Martinez A, Casal JI. Targeting the extracellular domain of fibroblast growth factor receptor 3 with human single-chain fv antibodies inhibits bladder carcinoma cell line proliferation. Clin Cancer Res 2005; 11(17):6280.